Skip to main content
Sign In

University of Colorado Denver

University of Colorado Denver School of Medicine
 

Lynn E. Heasley

Professor and Chair


Lynn Heasley
Lynn E. Heasley

Contact Information:
Department of Craniofacial Biology
School of Dental Medicine
Mail Stop 8120, RC1-South, Room L18 11100
12801 E. 17th Ave.
Aurora, CO  80045

Phone: 303-724-4578
Fax: 303-724-4580
Email: lynn.heasley@ucdenver.edu

Education:

  • PhD (Pharmacology), University of California at San Diego

Postdoctoral Training:

  • Department of Biochemistry, University of Massachusetts Medical Center, Worcester, MA
  • Division Basic Sciences, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO

Departmental Affiliations:

  • Craniofacial Biology, School of Dental Medicine
  • Department of Pharmacology, School of Medicine

Graduate Program Affiliations:

  • Biomedical Sciences Program (BSP)
  • Medical Scientist Training Program (MSTP)
  • Pharmacology
  • Cancer Biology Program

 Research Interests

My lab investigates autocrine and paracrine signaling through receptor tyrosine kinases, both as oncogene drivers and as acquired or intrinsic resistance mechanisms to targeted therapeutics. Our studies reveal that multiple families of receptor tyrosine kinases engage in autocrine growth stimulation in lung cancer, head and neck cancer and malignant mesothelioma cell lines. Moreover, our studies highlight specific receptor tyrosine kinases for their functioning within a co-activation network such that clinically-relevant tumor cell killing requires treatment with combinations of inhibitors, not monotherapy. Our experimental strategy involves functional genomics approaches to define signaling components functioning within the network and pharmacological approaches to identify inhibitors that can be translated to clinical applications. We rely on molecular studies with cultured cancer cell lines and in vivo approaches with immune deficient mice bearing orthotopically implanted cancer cell lines to pre-clinically validate promising therapeutics.

3

 Program and Center Affiliations

Training faculty member in Cancer Biology, Pharmacology and Biomedical Sciences graduate programs
Member, University of Colorado Cancer Center
4

 Current Trainees

Emily Kleczko, Cancer Biology graduate student5

 Publications

Marek, L., Ware, K., Fritzsche, A., Hercule, P., Helton, W.R., Smith, J.E., McDermott, L.A., Coldren, C.D., Nemenoff, R.A., Merrick, D.T., Helfrich, B.A., Bunn, P.A., Jr., and Heasley, L.E. (2009) FGF and FGFR-mediated autocrine signaling in non-small cell lung cancer cells. Mol. Pharmacol., 75:196-207. PMCID: PMC2669785  
 
Kono, S.A., Marshall, M.E., Ware, K.E., and Heasley, L.E. (2009) The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist. Updat. 12:95-102. PMCID: PMC2763047
 
Ware, K.E., Marshall, M.E., Heasley, L.R., Marek, L., Hinz, T.K., Hercule, P., Helfrich, B.A., and Heasley, L.E. (2010) Rapidly acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE, 5(11):e14117. PMCID: PMC2994708
 
Marshall, M.E., Hinz, T.K., Kono, S.A., Singleton, K.R., Bichon, B., Ware, K.E., Marek, L., Frederick, B.A., Raben, D. and Heasley, L.E. (2011) Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 17:5016-5025. PMCID: PMC3149730
 
Kono SA, Heasley LE, Doebele RC, Camidge DR. (2012) Adding to the mix: Fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 12:107-23. PMCID: PMC3418220
 
Linger RMA, Cohen RA, Cummings CT, Sather, S, Migdall-Wilson J, Middleton DHG, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, and Graham DK (2012) Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth, and enhances chemosensitivity of human non-small cell lung cancer. Oncogene PMCID: PMC3502700
 
Ware KE, Hinz TK, Marek L, Helfrich BA, Astling D, Tan AC, and Heasley, LE. (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2:e39. PMCID: PMC3641357
 
Singleton KR, Kim J, Hinz TK, Marek LA, Casas-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. (2013) A receptor tyrosine kinase network comprised of FGFRs, EGFR, ERBB2 and MET drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol 83(4):882-93. PMCID: PMC3608435
 

Göke F, Bode M, Franzen A, Kirsten R, Goltz D, Göke A, Sharma R, Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van Bremen T, Bootz F, Heasley LE, Schröck A, Perner S. (2013) Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol. Epub ahead of print, PMID: 23619603

6